When considering the whole cohort of TFR patients, PB CD26+ CML LSCs were measurable in 74/112 (66%) patients with a median number of 0.015/μL (range 0.006–0.76). Here, DPP4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.